Kite and Appia Bio collaborate to research and develop Allogeneic cell therapies for cancer
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
He will be stationed at the company HQ in Bengaluru, India
CDSCO to fast-track trials and approval for COVID19 vaccine
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
Five seats reserved for Wards of COVID warriors in central MBBS admission
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
Subscribe To Our Newsletter & Stay Updated